e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
State of the art session: Interstitial lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
An evidence-based and step-wise approach to treat pulmonary sarcoidosis with old and new drugs
R. Baughman (Cincinnati, United States of America)
Source:
International Congress 2019 – State of the art session: Interstitial lung diseases
Session:
State of the art session: Interstitial lung diseases
Session type:
Symposium
Number:
3525
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Baughman (Cincinnati, United States of America). An evidence-based and step-wise approach to treat pulmonary sarcoidosis with old and new drugs. International Congress 2019 – State of the art session: Interstitial lung diseases
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Sheeba Jobanputra - 10.02.2020 11:11
very comprehensive overview of treatment of sarcoidosis
You must
Login
to comment this presentation.
Related content which might interest you:
Pulmonary sarcoidosis
Definition and history of sarcoidosis
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
How we can modify the steroid insensitivity in patients with chronic obstructive pulmonary disease? The new pharmacological approach to old problem
Source: Annual Congress 2011 - COPD management
Year: 2011
Applying pharmacogenomics to pulmonary arterial hypertension (PAH): A target-based approach to therapy
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Subcutaneous treprostinil: a new therapeutic approach for idiopathic paediatric pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches
Source: Eur Respir J 2006; 28: 463-465
Year: 2006
Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal
Source: Eur Respir Rev 2012 21:259-262
Year: 2012
A pragmatic guide to choosing biologic therapies in severe asthma
Source: Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021
Year: 2021
A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease
Source: Eur Respir J, 58 (6) 2100276; 10.1183/13993003.00276-2021
Year: 2021
Treating sarcoidosis and potential new drugs
Source: Eur Respir Monogr 2022; 96: 328-336
Year: 2022
The multidisciplinary approach in the diagnosis of idiopathic pulmonary fibrosis: a patient case-based review
Source: Eur Respir Rev 2015; 24: 69-77
Year: 2015
What the pulmonary specialist should know about the new inhalation therapies
Source: Guideline 2011
Year: 2011
What the pulmonary specialist should know about the new inhalation therapies
Source: Eur Respir J 2012; 39: 1055-1056
Year: 2012
What the pulmonary specialist should know about the new inhalation therapies
Source: Eur Respir J 2012; 39: 1054-1055
Year: 2012
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
Source: Eur Respir J 2015; 46: 243-249
Year: 2015
The clinical efficacy of pulmonary hypertension-specific agents in idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD
Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers
Year: 2006
An algorithmic approach for the treatment of severe uncontrolled asthma
Source: ERJ Open Res, 4 (1) 00125-2017; 10.1183/23120541.00125-2017
Year: 2018
Searching for chronic obstructive pulmonary disease in the over 65 people: suggestions for a cost-effective approach
Source: Eur Respir J 2004; 24: Suppl. 48, 360s
Year: 2004
The new definition of pulmonary hypertension
Source: Eur Respir J 2009; 34: 790-791
Year: 2009
Which are the best methods to manage COPD patients in the post-COVID era?
Source: Virtual Congress 2021 – Part I: restarting COPD care in the post-COVID era
Year: 2021
Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science
Source: Eur Respir J 2016; 47:1615-1617
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept